« Return to News | Drug Sponsors

Pfizer backs out of pact with Biotica

Thursday, August 4, 2011 11:12 AM

Pfizer has returned the rights to a rapamycin analogue program it has been running to explore the potential of diseases such as multiple sclerosis and lupus to the UK's Biotica Technology, according to PharmaTimes.

The privately-owned group has regained full rights to the program which began after a deal was signed in 2006 with Wyeth (acquired by the US giant in October 2009). Since then, Pfizer has investigated these compounds in several diseases, "and in particular has extensively profiled candidate drugs in MS and systemic lupus erythematosus.”

Biotica says it intends to continue development in these indications but Pfizer is cutting back on its research activities and the project has been terminated. Mary Collins, chief scientific officer at the latter's immunology and autoimmunity research unit, said Pfizer had "enjoyed a productive collaboration with Biotica,” and the decision to return this program was made as part of its portfolio review process.

Edward Hodgkin, Biotica's chief executive, said, "Our compounds are supported by a strong data package generated by Pfizer, and show evidence of meaningful differentiation in diseases with significant unmet need."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.